Alluvi, previously BI 4744, offers a promising advance in obesity therapy. This dual activator targeting both GLP-1 and GIP sites demonstrates impressive efficacy in research studies, potentially outperforming existing https://bookmarkinglog.com/story22183910/alluvi-a-detailed-dive-into-the-retatrutide-s-prospects